Home › Cancer (all types) › NCT05371756

The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers.

The Texas Immuno-Oncology Biorepository: Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers That Predict Benefit/Resistance to Cancer Therapeutics.

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Participant is over 18 years of age at the time of signing the informed consent form.
* Participant is able and willing to sign an informed consent form.
* Participant is suspected by a provider of being at risk for developing cancer,

OR

* Participant has confirmed or clinically suspected malignancy by a provider. This includes but is not limited to:

  1. Participants who may be candidates for or are scheduled to receive standard of care immunotherapy treatment for the first time for their current cancer diagnosis, regardless of any prior non-immunotherapy treatment.
  2. Participants who are enrolled in a clinical trial to receive an investigational, novel immunotherapy drug for the first time for their current cancer diagnosis.
  3. Participants who may be surgical candidates for their current cancer diagnosis, regardless of any prior treatment.

Exclusion Criteria:

* Participant is unable or unwilling to donate blood.
* Concurrent medical or psychiatric condition or disease that may compromise the ability to give documented informed consent, is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study.

About the study

The purpose of the Texas Immuno-Oncology Biorepository (TIOB) is to collect and store well-defined and well-annotated serial biospecimens of tissue, blood, urine and stool in a longitudinal manner from cancer patients who are receiving either standard of care surgical interventions and or FDA approved immunotherapeutics across the largest not-for-profit health system in Texas. Comprehensive clinical and radiological data from a diverse population of patients with different racial, social and ethnic backgrounds matched with serial biospecimens over a patients journey with cancer marks the TIOB as a unique research facility.

Sponsor: Baylor Research Institute · Participants: 10,000 · Started: Sep 11, 2020

Contact the study team

• Pukar Ratti, MSChE, MSHCM · Phone: 214-818-8472

Official record on ClinicalTrials.gov — NCT05371756

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.